Adaptimmune Therapeutics plc - ROE
ADAP
Price:
$0.0485
Market Cap:
$10.60M
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies. Its primary focus is on addressing solid tumors in patients across the United States and the United Kingdom. At the core of its approach is the specific peptide enhanced affinity receptor (SPEAR) T-cell platform, designed to precisely identify cancer targets. The company's pipeline features several key candidates: ADP-A2M4 is in advanced clinical development, with Phase II trials underway for synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1), as well as for head and neck cancer (SPEARHEAD-2). Additionally, it is undergoing Phase I assessment for a wide ...[Read more]
Industry
Biotechnology
IPO Date
2015-05-06
Stock Exchange
NASDAQ
Ticker
ADAP
PE Ratio
[-0.07]
ROE
[472.78%]
Current Ratio
[1.52]
Dividend Yield
[0%]
Enterprise Value
[33.22M]
Dividend History
The ROE as of June 2026 (TTM) for Adaptimmune Therapeutics plc (ADAP) is 472.78%
According to Adaptimmune Therapeutics plc’s latest financial reports and current stock price. The company's current ROE is 472.78%. This represents a change of -495.24% compared to the average of -119.62% of the last 4 quarters.
Adaptimmune Therapeutics plc (ADAP) Historical ROE (quarterly & annually)
How has ADAP ROE performed in the past?
The mean historical ROE of Adaptimmune Therapeutics plc over the last ten years is -143.84%. The current 472.78% ROE has changed -428.70% with respect to the historical average. Over the past ten years (40 quarters), ADAP's ROE was at its highest in in the March 2025 quarter at 127.13%. The ROE was at its lowest in in the December 2024 quarter at -626.34%.
Average
-143.84%
Median
-59.92%
Minimum
-597.64%
Maximum
-8.32%
Adaptimmune Therapeutics plc (ADAP) ROE by Quarter and Year
Discovering the peaks and valleys of Adaptimmune Therapeutics plc ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 418.08%
Maximum Annual ROE = -8.32%
Minimum Annual Increase = -98.42%
Minimum Annual ROE = -597.64%
| Year | ROE | Change |
|---|---|---|
| 2024 | -597.64% | 107.38% |
| 2023 | -288.19% | 42.61% |
| 2022 | -202.08% | 163.27% |
| 2021 | -76.76% | 101.33% |
| 2020 | -38.12% | -65.64% |
| 2019 | -110.94% | 186.76% |
| 2018 | -38.69% | 11.96% |
| 2017 | -34.55% | -19.80% |
| 2016 | -43.08% | 418.08% |
| 2015 | -8.32% | -98.42% |
Adaptimmune Therapeutics plc (ADAP) Average ROE
How has ADAP ROE performed in the past?
The current ROE of Adaptimmune Therapeutics plc (ADAP) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-362.63%
5-year avg
-240.56%
10-year avg
-143.84%
Adaptimmune Therapeutics plc (ADAP) ROE vs. Peers
How is ADAP’s ROE compared to its peers?
Adaptimmune Therapeutics plc’s ROE is greater than Ernexa Therapeutics Inc. (-263.68%), less than Lunai Bioworks Inc. (892.52%), greater than BioLineRx Ltd. (-47.76%), less than Moleculin Biotech, Inc. (3.11%), greater than Adlai Nortye Ltd. (-414.01%), less than Apollomics, Inc. (288.40%), greater than GeoVax Labs, Inc. (-709.51%), greater than Lipocine Inc. (-66.69%), greater than Tharimmune, Inc. (-36.93%), greater than OSR Holdings, Inc. (-15.90%),
| Company | ROE | Market cap |
|---|---|---|
| -263.68% | $1.95M | |
| 892.52% | $17.14M | |
| -47.76% | $13.75M | |
| 3.11% | $15.37M | |
| -414.01% | $536.11M | |
| 288.40% | $19.31M | |
| -709.51% | $1.28M | |
| -66.69% | $13.52M | |
| -36.93% | $139.94M | |
| -15.90% | $9.63M |
Build a custom stock screener for Adaptimmune Therapeutics plc (ADAP) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Adaptimmune Therapeutics plc using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Adaptimmune Therapeutics plc (ADAP) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Adaptimmune Therapeutics plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Adaptimmune Therapeutics plc's ROE?
How is the ROE calculated for Adaptimmune Therapeutics plc (ADAP)?
What is the highest ROE for Adaptimmune Therapeutics plc (ADAP)?
What is the 3-year average ROE for Adaptimmune Therapeutics plc (ADAP)?
What is the 5-year average ROE for Adaptimmune Therapeutics plc (ADAP)?
How does the current ROE for Adaptimmune Therapeutics plc (ADAP) compare to its historical average?